Insider Transactions in Q1 2022 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Margaret G Mcglynn Director |
SELL
Open market or private sale
|
Direct |
5,000
-41.03%
|
$1,310,000
$262.21 P/Share
|
|
Mar 31
2022
|
Margaret G Mcglynn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.05%
|
$635,000
$127.54 P/Share
|
|
Mar 17
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,122
-4.2%
|
$530,500
$250.06 P/Share
|
|
Mar 17
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,171
-3.22%
|
$792,750
$250.59 P/Share
|
|
Mar 17
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,833
-2.82%
|
$708,250
$250.67 P/Share
|
|
Feb 25
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,572
-4.61%
|
$1,749,132
$231.09 P/Share
|
|
Feb 25
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
325
-0.13%
|
$74,750
$230.94 P/Share
|
|
Feb 24
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,038
-12.15%
|
$1,370,626
$227.86 P/Share
|
|
Feb 24
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,246
-10.02%
|
$1,644,842
$227.86 P/Share
|
|
Feb 24
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,242
-2.43%
|
$281,934
$227.86 P/Share
|
|
Feb 24
2022
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,246
-5.57%
|
$1,644,842
$227.86 P/Share
|
|
Feb 24
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
12,141
-11.89%
|
$2,756,007
$227.86 P/Share
|
|
Feb 24
2022
|
Joy Liu SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,554
-9.71%
|
$352,758
$227.86 P/Share
|
|
Feb 24
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
7,368
-13.26%
|
$1,672,536
$227.86 P/Share
|
|
Feb 24
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,590
-4.88%
|
$587,930
$227.86 P/Share
|
|
Feb 24
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,189
-4.25%
|
$496,903
$227.86 P/Share
|
|
Feb 18
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,312
-1.65%
|
$996,072
$231.08 P/Share
|
|
Feb 18
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
519
-0.24%
|
$119,889
$231.36 P/Share
|
|
Feb 17
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-5.99%
|
$797,848
$232.51 P/Share
|
|
Feb 17
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,126
-5.4%
|
$957,232
$232.51 P/Share
|
|
Feb 17
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-6.31%
|
$797,848
$232.51 P/Share
|
|
Feb 17
2022
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,584
-6.19%
|
$1,991,488
$232.51 P/Share
|
|
Feb 17
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
8,236
-7.47%
|
$1,910,752
$232.51 P/Share
|
|
Feb 17
2022
|
Joy Liu SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
712
-4.26%
|
$165,184
$232.51 P/Share
|
|
Feb 17
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,497
-5.92%
|
$811,304
$232.51 P/Share
|
|
Feb 17
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-6.37%
|
$797,848
$232.51 P/Share
|
|
Feb 17
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,114
-7.13%
|
$954,448
$232.51 P/Share
|
|
Feb 17
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-6.25%
|
$797,848
$232.51 P/Share
|
|
Feb 14
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,444
-4.08%
|
$567,008
$232.02 P/Share
|
|
Feb 11
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,297
-0.94%
|
$539,795
$235.59 P/Share
|
|
Feb 11
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
290
-0.13%
|
$68,150
$235.39 P/Share
|
|
Feb 10
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,518
-5.35%
|
$833,766
$237.74 P/Share
|
|
Feb 10
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,040
-3.83%
|
$720,480
$237.74 P/Share
|
|
Feb 10
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-4.28%
|
$577,569
$237.74 P/Share
|
|
Feb 10
2022
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,031
-2.14%
|
$718,347
$237.74 P/Share
|
|
Feb 10
2022
|
Joy Liu SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-2.76%
|
$112,338
$237.74 P/Share
|
|
Feb 10
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,491
-4.05%
|
$590,367
$237.74 P/Share
|
|
Feb 10
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
979
-1.78%
|
$232,023
$237.74 P/Share
|
|
Feb 10
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,230
-2.08%
|
$291,510
$237.74 P/Share
|
|
Feb 10
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,434
-4.24%
|
$576,858
$237.74 P/Share
|
|
Feb 02
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,660
-0.97%
|
$1,169,660
$251.08 P/Share
|
|
Feb 02
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+6.21%
|
$400,760
$86.52 P/Share
|
|
Feb 02
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
6,279
-5.38%
|
$1,525,797
$243.63 P/Share
|
|
Feb 02
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,040
-0.37%
|
$262,080
$252.61 P/Share
|
|
Feb 02
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,944
-4.88%
|
$736,000
$250.07 P/Share
|
|
Feb 01
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,108
+16.68%
|
-
|
|
Feb 01
2022
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,566
+39.32%
|
-
|
|
Feb 01
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
38,375
+16.46%
|
-
|
|
Feb 01
2022
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
23,988
+13.62%
|
-
|
|
Feb 01
2022
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
67,949
+16.01%
|
-
|